Gene Editing Drugs Developed to Combat Cholesterol
Highlights:
- At the American Heart Association's annual meeting, two experimental medications with innovative approaches to combatting bad cholesterol were unveiled
- Developed by Verve Therapeutics and Dr. Steven Nissen's team, these drugs deploy gene-editing and mRNA technologies
- While hailed as revolutionary, they await further testing and FDA approval before potential public availability
Amid the growing concerns about the side effects of weight-loss drugs, groundbreaking research presented at the annual meeting of the American Heart Association has unveiled two experimental medications showing significant promise in reducing bad cholesterol levels (1✔).
New Solutions for High Cholesterol
According to NBC News, these medications are not intended for weight loss but rather cater to individuals with a specific genetic predisposition. People genetically prone to high cholesterol can potentially use these drugs in conjunction with a balanced diet and regular exercise to better manage their risk of heart attack and stroke.
One of these treatments employs gene-editing techniques, while the other utilizes mRNA. The first, developed by Verve Therapeutics, uses base editing to target the PCSK9 gene responsible for producing LDL, commonly known as "bad" cholesterol.
‘The PCSK9 gene, targeted by Verve Therapeutics', is a key regulator of LDL ("bad") cholesterol production in the human body. #cholesterol #AHA #medindia’
Verve's co-founder and CEO, Dr. Sekar Kathiresan, describes the medication as a permanent eraser, eliminating the gene's ability to elevate cholesterol.
The second medication, reported by NBC News, is a pioneering therapy addressing lipoprotein(a) or Lp(a) - a perilous form of cholesterol. Individuals with elevated Lp(a) levels face a heightened risk of arterial fat buildup.
This genetic condition, as noted by Dr. Steven Nissen, the study's author, is traditionally challenging to treat. Nissen's team has developed lepodisiran, a drug akin to COVID-19 vaccines, targeting mRNA to stimulate the production of antibodies.
Awaiting Approval and Public Availability
Despite these promising developments, it will be some time before these medications are accessible to the public. Neither treatment has undergone human testing, necessitating further research and examination before potential approval by the Food and Drug Administration.Despite this cautious approach, experts at the meeting lauded the research findings as nothing short of revolutionary. Dr. Hugh Cassiere, director of critical care services at South Shore University Hospital, Northwell Cardiovascular Institute in New York, emphasized, "There is no way to categorize this other than revolutionary." Cassiere was not involved in either research project.
Reference:
- A single infusion of a gene-editing medicine may control inherited high LDL cholesterol - (https:newsroom.heart.org/news/a-single-infusion-of-a-gene-editing-medicine-may-control-inherited-high-ldl-cholesterol )
Source: Medindia
Cite this Article ⇣⇡
Please use one of the following formats to cite this article in your essay, paper or report:
-
APA
Dr. Pavithra. (2023, November 16). Gene Editing Drugs Developed to Combat Cholesterol. Medindia. Retrieved on Sep 28, 2024 from https://www.medindia.net/news/healthwatch/gene-editing-drugs-developed-to-combat-cholesterol-214214-1.htm.
MLA
Dr. Pavithra. "Gene Editing Drugs Developed to Combat Cholesterol". Medindia. Sep 28, 2024. <https://www.medindia.net/news/healthwatch/gene-editing-drugs-developed-to-combat-cholesterol-214214-1.htm>.
Chicago
Dr. Pavithra. "Gene Editing Drugs Developed to Combat Cholesterol". Medindia. https://www.medindia.net/news/healthwatch/gene-editing-drugs-developed-to-combat-cholesterol-214214-1.htm. (accessed Sep 28, 2024).
Harvard
Dr. Pavithra. 2023. Gene Editing Drugs Developed to Combat Cholesterol. Medindia, viewed Sep 28, 2024, https://www.medindia.net/news/healthwatch/gene-editing-drugs-developed-to-combat-cholesterol-214214-1.htm.